ORs of inhospital mortality and HRs of overall mortality and adverse cardiac outcomes associated with RA and SLE
| Adverse outcomes | Control group (n=170 762) | Patients with autoimmune diseases | |
|---|---|---|---|
| Patients with RA (n=525) | Patients with SLE (n=211) | ||
| Inhospital mortality (%) | 3438 (2.0) | 22 (4.2) | 11 (5.2) |
| Crude OR (95% CI) | 1.00 | 2.13 (1.39 to 3.27)*** | 2.68 (1.46 to 4.91)*** |
| Adjusted OR (95% CI)† | 1.00 | 1.73 (1.11 to 2.68)* | 3.81 (2.02 to 7.16)*** |
| Overall mortality (%) | 45 489 (26.6) | 199 (37.9) | 71 (33.6) |
| Crude HR (95% CI) | 1.00 | 1.74 (1.51 to 2.00)*** | 1.53 (1.21 to 1.93)*** |
| Adjusted HR (95% CI)‡ | 1.00 | 1.55 (1.35 to 1.79)*** | 2.20 (1.74 to 2.78)*** |
| Ischaemic events (%) | 49 586 (29.0) | 157 (29.9) | 62 (29.4) |
| Crude HR (95% CI) | 1.00 | 1.21 (1.03 to 1.41)* | 1.18 (0.92 to 1.51) |
| Adjusted HR (95% CI)‡ | 1.00 | 1.18 (1.01 to 1.39)* | 1.17 (0.91 to 1.50) |
| Repeat revascularisation (%) | 61 872 (36.2) | 171 (32.6) | 81 (38.4) |
| Crude HR (95% CI) | 1.00 | 1.00 (0.86 to 1.16) | 1.23 (0.99 to 1.52) |
| Adjusted HR (95% CI)‡ | 1.00 | 1.06 (0.92 to 1.24) | 1.27 (1.02 to 1.58)* |
| Any MACE | 95 824 (56.1) | 321 (61.1) | 135 (64.0) |
| Crude HR (95% CI) | 1.00 | 1.24 (1.11 to 1.38)*** | 1.34 (1.13 to 1.58)*** |
| Adjusted HR (95% CI)‡ | 1.00 | 1.20 (1.07 to 1.34)** | 1.47 (1.24 to 1.75)*** |
*p<0.05, **p<0.01, *** p<0.001.
†Based on the multiple logistic regression analysis with adjustment for age, sex, medical comorbidities, ACS, stenting and hospital levels.
‡Based on Cox proportional hazards regression model with adjustment for age, sex, medical comorbidities, ACS, stenting and hospital levels.
ACS, acute coronary syndrome; MACE, major adverse cardiac events; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.